New Drug May Reduce Heart Attack Damage

In ICU
Mon, 27 Jul 2009

The drug, known as Dz13, specifically targets and neutralises the gene responsible for inflammation and muscle death in the aftermath of a heart attack, preclinical trials have found.

The drug also reduces incidental cell and tissue death resulting from life-saving interventions such as balloon angioplasty and stent placements used to open blocked arteries, or from the delivery of clot-busting drugs.

Significantly, the heart

«« Lung Volume Reduction Surgery Shown To Prolong And Improve Life For Some Emphysema Patients

Can The Relationship Between Doctors And Drug Companies Ever Be A Healthy One? »»

Latest Articles

Decision-Making in the ICU
- ICU Journal Article
- 19/04/2024
Decision-making in the ICU is a multifaceted process that involves clinical assessment, collaboration among multidisciplinary teams, ethical considerations, evidence-based practice, communication, and continuous adaptation to evolving clinical scenarios. Balancing the complex factors requires
READ MORE
Dealing With Uncertainty in ICU Decision-Making: A Practical Guide
- ICU Journal Article
- 19/04/2024
When the stakes are high, and the path ahead is uncertain, the decisions made, especially if a patient continues to worsen, can be sources of self-torment and can haunt us for a long time. Our goal is to suggest ways to steer decision-making for intensivists in the face of uncertainty by prop
READ MORE
The Least Bad Decision: Crisis Standards of Care After the Pandemic
- ICU Journal Article
- 19/04/2024
COVID-19 was an emergency that lasted for years and left few regions of the world untouched. The pandemic shone a spotlight on both the strengths and weaknesses of our disaster planning. What worked, what did not, and how can we better plan for future emergencies? The COVID-19 pandemic fo
READ MORE

The drug, known as Dz13, specifically targets and neutralises the gene responsible for inflammation and muscle death in the aftermath of a heart attack,...